CreamA Cream article
Article

New Anti-Covid Drug That Reduces Dependence on Oxygen Will Be Out in a Month: DRDO Scientist

Dr.Venkat
 
The new anti-Covid oral drug developed by the DRDO will help hospitalised patients and reduce their supplemental oxygen dependence. The drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL) in Hyderabad. The drug, which comes in powder form in a sachet and is taken orally by dissolving it in water, was approved by the Drugs Controller General of India (DCGI) for emergency use as an adjunct therapy.

The 2 DG drug, like glucose, spreads through the body, reaches the virus-infected cells and prevents virus growth by stopping viral synthesis and destroys the protein’s energy production. The drug also works on virus infection spread into lungs which help us to decrease patients dependability on oxygen.
2-Deoxy-d-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. As such; it acts to competitively inhibit the production of glucose-6-phosphate from glucose at the phosphoglucoisomerase level .
The authors suggest that 2-DG works, in part, by increasing the expression of Brain-derived neurotrophic factor (BDNF), Nerve growth factor (NGF), Arc (protein) (ARC), and Basic fibroblast growth factor (FGF2).

Read More